GE HealthCare has received U.S. FDA 510(k) clearance and CE Marking for its Allia Moveo imaging platform, with the system already installed at its first global site, Hôpital Marie-Lannelongue in France. The launch marks the latest addition to the company’s Allia platform, initially unveiled at RSNA 2025.

Designed for interventional procedures in cardiovascular, vascular, nonvascular, and surgical settings, Allia Moveo features a compact, mobile C-arm system. The device integrates AI-enabled tools and a wireless design intended to improve navigation and adaptability in space-constrained interventional suites.

Hôpital Marie-Lannelongue, a national reference center for complex aortic care, is using the system for flexible cone-beam CT imaging in vascular and cardiac interventions. The unit is built with a wide-bore design and an ergonomic table system to support patient access and positioning, regardless of body size.
“My initial experience with Allia Moveo has been incredible, it’s a real game changer,” said Dr. Stephan Haulon, head of the aortic center and vascular surgery at the hospital. “One of the major milestones of this new system is having access to the reconstruction of the cone beam CT with CleaRecon DL, which is AI driven and gives you much better image quality.”

Allia Moveo includes several advanced imaging features, such as CleaRecon DL for reducing streak artifacts in arterial imaging, Motion Freeze to address respiratory motion artifacts, and metallic artifact reduction to enhance anatomical detail. The system is also compatible with GE HealthCare's ASSIST software suite and third-party platforms.

Following the installation in France, Baylor St. Luke’s Medical Center in Houston became the first U.S. site to adopt the platform.

“This innovative platform enhances how our clinicians navigate complex minimally invasive procedures by improving mobility, image clarity, and workflow efficiency,” said Dr. Brad Lembke, president of the hospital.

Cardiology Homepage